Drug intelligence / Profile preview

eltanolone

Development stage: Unknown
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration: Intravenous

Overview

Eltanolone (also known as pregnanolone) is an endogenous neuroactive steroid biosynthesized from progesterone. It acts primarily as a positive allosteric modulator of the GABAA receptor and as a negative allosteric modulator of the glycine receptor. Eltanolone has sedative, anxiolytic, anesthetic, and anticonvulsant properties. It was investigated for use as an intravenous general anesthetic but was never marketed due to unwanted side effects such as occasional convulsions. Eltanolone is closely related to allopregnanolone (brexanolone), another neurosteroid with similar pharmacological effects.

Other names: pregnanolone

Targets

Glycine receptorGABRR (GABA-A receptor subunit rho)

Beyond the preview

Go deeper on eltanolone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on eltanolone.

Explore the full profile